XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
Follow XTLB
XTL Biopharmaceuticals Ltd. (XTLB) EV/Sales
As of 16 October 2026, XTL Biopharmaceuticals Ltd. (XTLB) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from −1.1× (March 2020) to 60.5× (February 2015); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 4.8× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APRE Aprea Therapeutics, Inc. compare | −35.7× |
| IMRN IMMURON compare | −3.5× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. | 1.3× |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| BOLT Bolt Biotherapeutics, Inc. compare | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)